bezafibrate


Also found in: Wikipedia.

bezafibrate

A cholesterol-lowering drug. Brand names are Bezalip, Bezalip Mono and Zimbacol XL.
References in periodicals archive ?
The fibrate drug bezafibrate was found in one study to reduce the incidence and delay the onset of type II diabetes in subjects with impaired fasting glucose.
Drug administered Findings of studies that do not support a negative association of HDL and cardiovascular risk Fibrates Bezafibrate Infarction Prevention Study * In patients with previous MI, treatment with bezafibrate significantly increased HDL-C, but did not significantly reduce risk of MI or sudden death [BIP Study (34)] Other studies * In patients with low baseline HDL-C, treatment with fibrates elevated HDL-C, but did not confer an additional CVD risk reduction at up to 8 years of follow-up [Nicholls etal.
Therefore, they analyzed national registry mortality data and fasting triglyceride levels for 15,355 patients who had been screened for the Bezafibrate Infarction Prevention trial during 1990 and 1992.
The following are considered: CDDO-ethyl amide, CDDO-trifluroethylamide, pioglitazone, rosiglitazone, resveratrol, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), and bezafibrate [129].
63) Since the ATP crisis in IAE patients is enhanced by starvation other than thermal inactivation of CPT II, glucose supplementation and activation of glucose oxidation for ATP generation by DADA might be also an important option for the patients, in addition to treatment with bezafibrate (Fig.
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease-a historical prospective.
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome," European Journal of Pharmacology, vol.
Fibrates: Bezafibrate and gemfibrazil reduce serum triglycerides, VLDL and LDL, and increase HDL by increasing Apo-A and LDL-receptors.
Fibric acid derivatives, such as fenofibrate, bezafibrate and gemfibrozil, are preferred in the treatment of dyslipidemias associated with DM and metabolic syndrome than HMG-CoA reductase inhibitors as they are usually more effective for normalizing serum levels of HDL-Cholesterol and TG7.
Other fibrate medications include fenofibrate (TriCor) and bezafibrate (Bezalip).